Literature DB >> 15716302

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.

Philippe Remy1, Miroslava Doder, Andrew Lees, Nora Turjanski, David Brooks.   

Abstract

The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration of neurotransmitter systems other than dopamine might play a specific role in the occurrence of these affective disorders. We used [11C]RTI-32 PET, an in vivo marker of both dopamine and noradrenaline transporter binding, to localize differences between depressed and non-depressed patients. We studied eight and 12 Parkinson's disease patients with and without a history of depression matched for age, disease duration and doses of antiparkinsonian medication. The depressed Parkinson's disease cohort had lower [11C]RTI-32 binding than non-depressed Parkinson's disease cases in the locus coeruleus and in several regions of the limbic system including the anterior cingulate cortex, the thalamus, the amygdala and the ventral striatum. Exploratory analyses revealed that the severity of anxiety in the Parkinson's disease patients was inversely correlated with the [11C]RTI-32 binding in most of these regions and apathy was inversely correlated with [11C]RTI-32 binding in the ventral striatum. These results suggest that depression and anxiety in Parkinson's disease might be associated with a specific loss of dopamine and noradrenaline innervation in the limbic system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716302     DOI: 10.1093/brain/awh445

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  260 in total

1.  Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Authors:  Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers
Journal:  Neuropsychology       Date:  2011-12-05       Impact factor: 3.295

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Apathy and depression: separate factors in Parkinson's disease.

Authors:  Lindsey Kirsch-Darrow; Michael Marsiske; Michael S Okun; Russell Bauer; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2011-11       Impact factor: 2.892

Review 4.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

5.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

6.  Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.

Authors:  Shawn P Alter; Kristen A Stout; Kelly M Lohr; Tonya N Taylor; Kennie R Shepherd; Minzheng Wang; Thomas S Guillot; Gary W Miller
Journal:  Exp Neurol       Date:  2015-09-30       Impact factor: 5.330

7.  Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats.

Authors:  Li Li; Yun-Xiao Kang; Xiao-Ming Ji; Ying-Kun Li; Shuang-Cheng Li; Xiang-Jian Zhang; Hui-Xian Cui; Ge-Ming Shi
Journal:  CNS Neurosci Ther       Date:  2017-12-06       Impact factor: 5.243

8.  Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?

Authors:  Laura B Zahodne; Oscar Bernal-Pacheco; Dawn Bowers; Herbert Ward; Genko Oyama; Natlada Limotai; Frances Velez-Lago; Ramon L Rodriguez; Irene Malaty; Nikolaus R McFarland; Michael S Okun
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

Review 9.  A model for streamlining psychotherapy in the RDoC era: the example of 'Engage'.

Authors:  G S Alexopoulos; P Arean
Journal:  Mol Psychiatry       Date:  2013-11-26       Impact factor: 15.992

Review 10.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.